Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Qlife Holding AB ("Qlife" or the "Company"), a pioneer in clinical-grade home diagnostics, provides a year-end operational update on key issues.
Diabetes data
Egoo Health has achieved breakthrough precision in key diabetes biomarker test. The Egoo HbA1c blood test for diabetes management has achieved best-in-class precision with a coefficient of variation (CV) below 3%. This achievement positions Egoo as potentially the first home-use HbA1c test to meet the same stringent clinical and regulatory standards. The diabetes diagnostics market, with a focus on moving clinical diabetes management into home-use products represents a significant partnering opportunity.
Partnerships
The Company continues to prioritize strategic partnerships. During 2025, the Company entered into a non-binding Letter of Intent with a Top-20 pharmaceutical company and has since maintained an active dialogue, progressing in line with the agreed roadmap. In parallel, Qlife is experiencing growing interest from global in vitro diagnostics (IVD) companies, driven by the positive outcome of the Birmingham clinical study and the demonstrated best-in-class precision of the Egoo HbA1c blood test.
Submission EGOO PHE proof-of-concept product
The Company has started to upload the technical files for the Egoo Phe System for PKU-management to a Notified Body (authority). This process is expected to be finalized by mid-January, at which point the Company will have submitted its first application under the new In Vitro Diagnostics Regulation (IVDR). This represents a major milestone, not only for the specific test, but also in validating the regulatory framework of the Egoo Health platform, which is an important step in the Company's partnerships strategy.
Cost reduction model
The Company will continue to maintain a lean cost structure by having typically resource-intensive functions done by strategic partner, Hipro Biotechnology. This close collaboration provides Qlife with a significant advantage: the ability to operate with lower overhead compared to traditional IVD companies. By having Hipro manage most of the costs associated with development, regulatory and compliance processes, production, and sales & marketing, Qlife can sustain an efficient organisation and a highly competitive cost model.
CEO year-end statement
"During 2025, we have established the fundamentals for the Egoo Health product platform that needs to be in place to become an attractive partnering opportunity for major diagnostics and pharmaceutical companies. As we enter 2026, I believe we are now well positioned to break into the new personalized Dx/Rx paradigm and to partner with industry leaders that can take our innovative Egoo Health platform to the next level across multiple applications", says Thomas Warthoe, CEO Qlife.
For more information, please contact:
Thomas Warthoe, Chief Executive Officer (CEO)
Phn: +45 21 63 35 34
E-mail: tw@egoo.health